Show
Sort by
-
- Journal Article
- A1
- open access
ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020)
-
- Journal Article
- A1
- open access
ARIA‐EAACI care pathways for allergen immunotherapy in respiratory allergy
-
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps : a systematic review for the EAACI guidelines
-
- Journal Article
- A1
- open access
Management of anaphylaxis due to COVID‐19 vaccines in the elderly
-
COVID‐19 pandemic : practical considerations on the organization of an allergy clinic : an EAACI/ARIA position paper
-
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients : an ARIA-EAACI statement
-
Handling of allergen immunotherapy in the COVID-19 pandemic : an ARIA-EAACI statement
-
Prioritizing research challenges and funding for allergy and asthma and the need for translational research : the European Strategic Forum on Allergic Diseases
-
Severe asthma : entering an era of new concepts and emerging therapies : highlights of the 4th International Severe Asthma Forum, Madrid, 2018
-
Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN